MMSI - Merit Medical Systems, Inc.
Freestone Grove Partners LP purchased a new position in Merit Medical Systems, Inc. (NASDAQ: MMSI) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,554 shares of the medical instruments supplier's stock, valued at approximately $1,148,000. Other hedge funds and other
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
American Capital Management Inc. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ: MMSI) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 104,967 shares of the medical instruments supplier's stock, valued at approximately $7,278,000. American Capital Management
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SOUTH JORDAN, Utah, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer of healthcare technology, today announced that Sheri Lewis has agreed to join Merit as Executive Vice President of Global Operations, effective August 31, 2026.
Merit Medical Systems (NASDAQ: MMSI) is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event. Parra said the company remains "hyper-focused" on executing its current CGI plan and does not want to "drop the football on
Merit Medical Systems NASDAQ: MMSI is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event.
Merit Medical Systems NASDAQ: MMSI is preparing its next long-range plan as the medical-device company works through a leadership transition, updates its reporting structure and seeks to build on recent revenue and margin momentum.
Merit Medical Systems, Inc. (MMSI) Presents at Bank of America SMID Cap Virtual Conference Transcript
Investors interested in Medical - Dental Supplies stocks are likely familiar with The Cooper Companies (COO) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
SOUTH JORDAN, Utah, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the upcoming investor conferences:
Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.
Merit Medical Systems Inc (NASDAQ:MMSI) posted better-than-expected earnings for the second quarter on Thursday.
Merit Medical Systems, Inc. (MMSI) Q2 2026 Earnings Call Transcript
Merit Medical (MMSI) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.01 per share a year ago.
The headline numbers for Merit Medical (MMSI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Financial Highlights† Reported revenue of $418.8 million, up 10% Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively GAAP operating margin of 14.4%, compared to 12.3% in prior year period Non-GAAP operating margin* of 22.6%, compared to 21.2% in prior year period GAAP EPS $0.65, up 20% Non-GAAP EPS* $1.19, up 18% Cash flow from operations of $110.0 million year-to-date, down 11% Free cash flow* generation of $76.6 million year-to-date, down 14% † Comparisons above are calculated for the current quarter compared with the second quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.